Participant characteristics at baseline.
ADVERSE EVENTS, DISEASE
Mean ± standard deviation or frequency (%) provided when applicable.All enrolled participants completed all study timepoints, however not all outcome measures could be performed due to disease severity, progression or adverse events (for example, falls with injury interfered with the 2MWT). On completion of the 26-week pilot study, a 12-month Open-Label Extension (OLE) was conducted at the request of 12 study participants, with reassessment at 6 and 12-month timepoints. Two participants did not enrol in the open-label study due to self-report of undesirable side effects relating to mood and/or libido observed whilst on testosterone.